Heron Therapeutics (HRTX) Stock: Climbing On Strong Clinical Results

Heron Therapeutics Inc HRTX Stock NewsHeron Therapeutics Inc (NASDAQ: HRTX) is having an overwhelmingly strong start to the trading session this morning, and for good reason. The company announced clinical results that proved to be positive, leading to excitement among investors and sending the stock screaming for the top. Today, we’ll talk about the results, what we’re seeing from the stock, and what we’ll be watching for with regard to HRTX ahead.

HRTX Announces Positive Clinical Results

As mentioned above, Heron Therapeutics is having an incredible day in the market today after announcing positive results from two completed Phase 3 clinical trials. In a press release issued early this morning, the company announced that the investigation agent, HTX-011, achieved all primary and key secondary endpoints in both clinical trials. In the release, HRTX said that the trials demonstrated significant reductions in both pain intensity and the use of opioid rescue medications through 72 hours following surgery.




In the release, the company reminded investors that HTX-011 is the first and only long-acting local anesthetic to demonstrate significantly reduced pain and opioid use in Phase 3 studies when compared to bupivacaine solution, the current standard of care. In a statement, Barry D. Quart, Pharm.D., CEO at HRTX, had the following to offer:

With today’s results, HTX-011 is the only locally administered anesthetic to demonstrate superior pain relief and a reduction in opioid use as compared to not only placebo, but also the current standard-of-care, bupivacaine solution, in Phase 3 studies… We look forward to submitting a New Drug Application for HTX-011 to the U.S. Food and Drug Administration in the second half of 2018. If approved, we believe that HTX-011 could have a significant impact on the opioid crisis by reducing the use of opioids after surgery, while at the same time allowing patients to experience less pain.

What We’re Seeing From The Stock 

As investors, one of the first lessons that we learn is that the news moves the market. In this particular case, the news proved to be overwhelmingly positive. With the strong Phase 3 clinical results, Heron Therapeutics is one step closer to bringing HTX-011 to regulatory approval and commercialization. So, it’s no surprise to see that the stock is making a run for the top in the market today. Currently (11:30), HRTX is trading at $27.10 per share after a gain of $5.60 per share (26.05%) thus far today.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

What We’ll Be Watching For Ahead

Moving forward, the CNA Finance team will continue to keep a close eye on HRTX. In particular, we’re interested in following the story surrounding HTX-011, as the results proved to be overwhelmingly positive. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!

Never Miss The News Again

Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!

Subscribe Today!

* indicates required


Leave a Comment